Compositions and Methods for Inhibiting Gene Expression of LPA
申请人:Arrowhead Pharmaceuticals, Inc.
公开号:US20170096665A1
公开(公告)日:2017-04-06
RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
SYNTHESIS OF ALKYL- AND ARYLPHOSPHONIC ACID MONOESTERS BY DIRECT ESTERIFICATION OF DIBASIC PHOSPHONIC ACIDS IN THE PRESENCE OF AN ARSONIC ACID CATALYST
作者:Michael D. Crenshaw
DOI:10.1080/10426500490464032
日期:2004.8
the monochloro monoester, or alcoholysis of a phosphonicacid anhydride generally is used to prepare monoesters of alkyl- and arylphosphonic acids. Limited cases have been reported for the esterification of a dibasic phosphonicacid to yield the monoester, and none of these methods are as simple as the analogous method for preparing carboxylic acid esters, in which the carboxylic acid is esterified